Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (DFPH) Equity Average (2020 - 2025)

Historic Equity Average for Oncology Institute (DFPH) over the last 6 years, with Q3 2025 value amounting to -$10.6 million.

  • Oncology Institute's Equity Average fell 14757.21% to -$10.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.6 million, marking a year-over-year decrease of 14757.21%. This contributed to the annual value of $30.3 million for FY2024, which is 6636.29% down from last year.
  • Latest data reveals that Oncology Institute reported Equity Average of -$10.6 million as of Q3 2025, which was down 14757.21% from -$2.0 million recorded in Q2 2025.
  • In the past 5 years, Oncology Institute's Equity Average ranged from a high of $128.0 million in Q2 2022 and a low of -$10.6 million during Q3 2025
  • In the last 5 years, Oncology Institute's Equity Average had a median value of $49.2 million in 2024 and averaged $61.2 million.
  • As far as peak fluctuations go, Oncology Institute's Equity Average soared by 220060.85% in 2021, and later tumbled by 14757.21% in 2025.
  • Over the past 5 years, Oncology Institute's Equity Average (Quarter) stood at $75.8 million in 2021, then surged by 65.54% to $125.6 million in 2022, then plummeted by 48.68% to $64.4 million in 2023, then tumbled by 85.2% to $9.5 million in 2024, then crashed by 211.47% to -$10.6 million in 2025.
  • Its Equity Average stands at -$10.6 million for Q3 2025, versus -$2.0 million for Q2 2025 and $4.3 million for Q1 2025.